Navigation Links
Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
Date:5/11/2010

HASBROUCK HEIGHTS, N.J., May 11 /PRNewswire/ -- Scientists from Zymes LLC, the University of Windsor (Ontario, Canada) and the National Research Council of Canada presented their research at the 2010 Experimental Biology meetings in Anaheim California on April 28th.  The paper entitled, "Protection of SNpc neurons by water soluble CoQ10 in a paraquat induced rat model of Parkinson's disease: The role of neurotrophic factors," describes a potential treatment for halting the progression of Parkinson's disease in an animal model using Zymes' water soluble CoQ10 (WS-CoQ10) formulation.  

Parkinson's disease (PD) is a neurodegenerative disorder that results from the progressive loss of select neurons in the brain.  Many studies show that mitochondrial dysfunction/oxidative stress is a major contributor to this disease.  An established animal model of paraquat-induced Parkinson's disease was used in this study.  Animals were given Zymes' water soluble CoQ10 in their drinking water with access 24 hours a day pre-treatment (prophylactic) and post-treatment (therapeutic). In these studies, Zymes' water soluble CoQ10 provided significant protection of dopaminergic neurons and a decrease in symptoms.  

"We are very excited about these early stage findings that support the use of Zymes' water soluble CoQ10 to halt the symptoms of Parkinson's disease," said Dr. Shelley Weinstock, Sr. VP of Research and Scientific Affairs.  In addition, in these studies, animals were exposed to the water soluble CoQ10 on a continuous basis in their water, suggesting that small doses, several times a day is a more effective method of administration than larger doses once or twice per day.  More research is needed to determine if Zymes' water soluble CoQ10 may be effective in halting the progression of Parkinson's disease in people.

About Zymes LLC:

Zymes LLC is a bioscience company based in Hasbrouck Heights, NJ that provides innovative solutions to its partners and consumers through proprietary science and technology, enabling new products to enhance the well-being of people. For more information please visit www.zymes.com.


'/>"/>
SOURCE Zymes LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Novozymes Launches Enzyme to Reduce Acrylamide in Food
2. Genencor Appoints New Executive Vice President - Technical Enzymes
3. DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production
4. ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
5. Novozymes Reports Strong 2008 Results
6. Albemarle Manufactures Zymes PTS, the Lead Compound in a Breakthrough Solubilization Technology
7. Zymes Omega Solutions Bottles and Launches the Worlds First Omega-3 Enhanced Water
8. Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
9. Reportlinker Adds Industrial Enzymes - A Global Market Report
10. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
11. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of company ... is accounted to two main factors. The first is the amazing customer service ... supplying FireflySci products all around the world. , 2016 was a tremendous sales year ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and Company) ... today that it will host a live webcast of its Annual ... (ET). The webcast can be accessed from the ... replay through Tuesday, January 31, 2017. ... About BD BD is a global ...
(Date:1/18/2017)... 18, 2017   Parent Project Muscular Dystrophy (PPMD) ... Duchenne muscular dystrophy (Duchenne) , today announced a ... Institute of Technology (NJIT) and Talem Technologies (Talem) as ... technology to assist people living with Duchenne. PPMD ... – an embedded computer, software, a force sensor and ...
(Date:1/18/2017)... ... 2017 , ... MYOLYN, which creates medical technology for people ... to the FDA, requesting clearance of the MyoCycle Home and the MyoCycle Pro ... , The submission marks a major milestone for the technology startup. MYOLYN spun ...
Breaking Biology Technology:
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Forecasts, 2015 - 2022," projects that the global biometric technology market is expected to ... 2016 to 2022. Continue Reading ... ...      ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017  For the thousands of ... , a global leader in connected health and biometric measurement devices and ... pressure monitors. On display in A&D Medical,s special CES ... monitors represent the ongoing expansion of the company,s WellnessConnected product ... ...
Breaking Biology News(10 mins):